Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Breast 4Gynecologic 3Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × poly(I).poly(c12,U) × Other hematologic neoplasm × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡